Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin

Anti-Cancer Drugs

Volumn 11, Issue 4, 2000, Pages 303-309

  Cufer, Tanja ^a   Pfeifer, Marija ^b   Vrhovec, Ivan ^a   Frangez, Robert ^c   Kosec, Marjan ^c   Mrhar, Ales ^c   Grabnar, Iztok ^c   Golouh, Rastko ^a   Vogric, Sonja ^a   Sikic, Branimir Ivan ^d  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenal gland; Cortisol; P glycoprotein; Valspodar; Xenobiotics

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; HYDROCORTISONE; MITOTANE; VALSPODAR; XENOBIOTIC AGENT;

ADRENAL CORTEX CELL; ADRENAL GLAND; ANIMAL TISSUE; ARTICLE; CATTLE; CONTROLLED STUDY; HYDROCORTISONE RELEASE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADRENAL GLANDS; ANIMALS; CATTLE; CYCLOSPORINS; DOXORUBICIN; HYDROCORTISONE; MITOTANE; P-GLYCOPROTEIN; PERFUSION;

EID: 0034044703     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200004000-00012     Document Type: Article

References (25)

1. 1. Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 1989; 16: 156-65.
2. 2. Gottesman MM, Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem 1988; 263: 12163-6.
3. 3. Harris AL, Hochhauser D. Mechanism of multidrug resistance in cancer treatment. Acta Oncol 1992; 31: 205-13.
4. 4. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137-71.
5. 5. Fisher GA, Lum BL, Hausdorff J, Sikic BI. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 1996; 32: 1082-8.
6. 6. Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P. SDZ PSC 833, a non-immunosupressive cyclosporin: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 1992; 50: 593-7.
7. 7. Dutt A, Priebe T, Teeter L. Postnatal development of organic cation transport and mdr gene expression in mouse kidney. J Pharmacol Exp Ther 1992; 261: 1222-30.
8. 8. Tatsuta T, Naito M, Oh-hara T, Sugawara T, Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992; 267: 20383-91.
9. 9. Thalhammer T, Stapf V, Gajdzik L, Graf J. Bile canalicular cationic dye secretion as a model for P-glycoprotein mediated transport. Eur J Pharmacol 1994; 270: 213-20.
10. 10. Zacherl J, Hamilton G, Thalhammer T, et al. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH. Cancer Chemother Pharmacol 1994; 34: 125-32.
11. 11. Borst P, Schinkel AH. What have we learned thus far from mice with disrupted P-glycoprotein genes? Eur J Cancer 1996; 32: 985-90.
12. 12. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC 833. J Clin Invest 1997; 100: 2430-6.
13. 13. Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM, Borst P. Absence of the mdrla P-glycoprotein mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin. Am J Clin Invest 1995; 96: 1698-705.
14. 14. Schinkel AH, Smit JJM, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
15. 15. Sugawara I, Nakahama M, Hamada H, Tsuruo T, Mori S. Apparent stronger expression in the human adrenal cortex than in the human adrenal medulla of Mr 170000-180000 P-glycoprotein. Cancer Res 1988; 84: 4611-4.
16. 16. Sugawara I, Hamada H, Nakahama M, et al. Further characterization of the human adrenal-derived P-glycoprotein recognised by monoclonal antibody MRK 16 reacting with only human P-glycoprotein. Jpn J Cancer Res 1989; 80: 1199-205.
17. 17. Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone. J Biol Chem 1992; 267: 24248-52.
18. 18. Van Kalken CK, Broxterman HJ, Pinedo HM, et al. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 1993; 67: 284-9.
19. 19. Wolf DC, Horwitz SB. P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid. Int J Cancer 1992; 52: 141-6.
20. 20. Yang C-PH, DePinho SG, Greenberger LM, Arceci RJ, Horwitz SB. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and endometrium of gravid uterus. J Biol Chem 1989; 264: 782-8.
21. 21. Barnes KM, Dickstein B, Cutler GB, Fojo T, Bates SE. Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 1996; 35: 4820-7.
22. 22. Cufer T, Vrhovec I, Skrk J, et al. Cyclosporine A increases serum cortisol levels in rabbits. Anti-Cancer Drugs 1995; 6: 615-8.
23. 23. Cufer T, Vrhovec I, Skrk J, Pfeifer M, Borstnar S, Sikic BI. Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits. Cancer Chemother Pharmacol 1998; 41: 517-21.
24. 24. Sheppard KE. Cyclosporine A and FK506 are potent activators of proopiomelanocortin-derived peptide secretion without affecting corticotrope glucocorticoid receptor function. J Neuroendocrinol 1995; 7: 833-40.
25. 25. Letronico AC, Chrousos GP. Extensive personal experience-adrenocorical tumors. J Clin Endocrinol Metab 1997; 82: 1317-22.